IQWiG

# Drug assessment at a glance: A26-49[1]

# Dupilumab (chronic spontaneous urticaria in children ≥2 to <12 years)

**4 November 2026**

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-49. The GBA decides on the added benefit.

# Research question for the benefit assessment

| | |
|---|---|
| **Population** | Children aged ≥2 years to <12 years with moderate to severe chronic spontaneous urticaria (CSU) with inadequate response to histamine H1 receptor (H1) antihistamines and who are naive to anti-immunoglobulin E (IgE) therapy for CSU |
| **Intervention** | dupilumab |
| **Comparator** | omalizumab, in combination with second-generation H1 antihistamines |
| **Outcomes** | At least one patient-relevant outcome |

# Overview of positive and negative effects

| | Size of the effects | Informative value of the effects |
|---|---|---|
| **Mortality** | ∅ | – |
| **Morbidity** | ∅ | – |
| **Symptoms** | ∅ | – |
| **Health-related quality of life** | ∅ | – |
| **Side effects** | ∅ | – |
| | ∅ No (suitable) data<br>↔ No advantage or disadvantage<br>↑ / ↓ Small advantage/disadvantage<br>↑↑ / ↓↓ Moderate advantage/disadvantage<br>↑↑↑ / ↓↓↓ Large advantage/disadvantage | – Not applicable<br>★ Low<br>★★ Moderate<br>★★★ High |

Overall: no advantage or disadvantage (no suitable data)

# Evidence base and noteworthy aspects

- No relevant study was identified.

# References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dupilumab (chronische spontane Urtikaria bei Kindern im Alter von ≥ 2 bis < 12 Jahren); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 03.11.2026]. URL: https://doi.org/10.60584/A26-49.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Dupilumab (Neues Anwendungsgebiet: chronische spontane Urtikaria, ≥ 2 Jahren bis < 12 Jahren) [online]. 2026 [Accessed: 03.11.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1341/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-49.html.

# Publisher details

**Publisher**

Institute for Quality and Efficiency in Health Care (IQWiG)

**Address**

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de